BriaCell 10-K: $34.9M FY2026 Loss, Going Concern Doubt Reaffirmed
BCTX sits 35% above its 52-week low of $2.6 on light trading volume (0.2× avg).
Summary
BriaCell's fiscal 2026 annual report shows a $34.9 million net loss, $28.7 million of operating cash burn, and a reaffirmed going-concern warning, leaving about $20.5 million of cash and investments to fund the Phase 3 program.
Key Events · Earnings and Guidance · BCTX
-
FY2026 Net Loss Widens to $34.9M
Net loss attributable to BriaCell was $34,904,262 for the year ended July 31, 2026, versus $26,311,867 in fiscal 2025, driven by research, development and clinical trial expenses of $29,236,508 (up from $21,270,678).
-
Going Concern Doubt Reaffirmed by Auditor
Accumulated deficit reached $146,659,826 at July 31, 2026, and MNP LLP's audit report includes a material-uncertainty going-concern paragraph; the company says it must raise additional equity or debt to continue.
-
Liquidity of ~$20.5M Against $28.7M Annual Burn
Cash and cash equivalents were $9,852,435 and short-term investments $10,688,277 at July 31, 2026, while net cash used in operating activities was $28,651,323 for the year.
-
FY2026 Raises Total ~$34.7M, Share Count Up Sharply
Equity financings generated aggregate gross proceeds of approximately $34,709,566 in fiscal 2026, including the January 2026 offering ($30.0 million) and June 2026 offering ($4.7 million); shares outstanding rose to 8,708,029 at July 31, 2026 from 1,883,906 a year earlier.
Analysis · BCTX · Life Sciences
The binding constraint here is the balance sheet, not the data. BriaCell burned $28.7 million of cash on operations in fiscal 2026 and ended July with $9.9 million in cash plus $10.7 million in short-term investments — roughly $20.5 million of liquidity against a loss run-rate that has been near $35 million a year. The auditor's report carries an explicit substantial-doubt going-concern paragraph, so another raise is a question of when, not if, and the company has already shown the price of that capital: about $34.7 million raised in fiscal 2026 across the January and June offerings, with shares outstanding now at 8.7 million versus 1.9 million a year earlier. The clinical story remains intact — the pivotal Phase 3 Bria-ABC study has passed seven DSMB reviews and enrollment passed 230 patients — but funding, not the data, will determine the timeline.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 38.5% of the 1020 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BCTX was trading at $3.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.4M. The 52-week trading range was $2.60 to $13.80. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.